Savara is a specialty pharmaceutical company focusing on innovative drugs for the treatment of serious and life-threatening rare respiratory diseases. The company currently has two products in clinical studies, AeroVanc and Molgradex. Both products are being developed for rare respiratory diseases that have a high need for more effective therapies.
AeroVanc for CF
AeroVanc is the first inhaled antibiotic being developed to address the growing problem of chronic methicillin-resistant Staphylococcus aureus (MRSA) lung infection in people with cystic fibrosis (CF).
Molgradex for PAP
Molgradex is the first treatment being developed for inhalation of GM-CSF for the treatment of patients suffering from a rare respiratory disease called pulmonary alveolar proteinosis (PAP).